Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Colorectal Neoplasms × ascrinvacumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1 Recurrence 1 Neoplasms 1 Neoplasm Metastasis 1 Mesothelioma, Malignant 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Hepatocellular 1 Camurati-Engelmann Syndrome 1 Advanced Solid Tumors 1

Interventions

Fluorouracil 233 Leucovorin 206 Oxaliplatin 196 Irinotecan 184 Bevacizumab 178 Capecitabine 130 Cetuximab 116 Panitumumab 59 Folfox protocol 59 regorafenib 45 pembrolizumab 37 IFL protocol 36 Colonoscopy 36 Nivolumab 30 Radiotherapy 29 Drug Therapy 25 Blood Specimen Collection 23 Gemcitabine 21 trifluridine tipiracil drug combination 19 Chemotherapy, Adjuvant 19 Surveys and Questionnaires 16 Neoadjuvant Therapy 15 Celecoxib 15 durvalumab 14 Surgical Procedures, Operative 14 Cyclophosphamide 14 Erlotinib Hydrochloride 13 Cisplatin 13 aflibercept 12 tremelimumab 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02116894 2019-03-14

REGAL-1

Duke University

Phase 1 Completed

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡